Ocular Therapeutix Inc (NASDAQ:OCUL) major shareholder Summer Road Llc acquired 363,636 shares of the stock in a transaction dated Tuesday, May 19th. The stock was acquired at an average cost of $5.50 per share, with a total value of $1,999,998.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Summer Road Llc also recently made the following trade(s):

  • On Tuesday, March 24th, Summer Road Llc bought 109,100 shares of Ocular Therapeutix stock. The stock was purchased at an average price of $4.92 per share, with a total value of $536,772.00.
  • On Thursday, March 19th, Summer Road Llc bought 40,900 shares of Ocular Therapeutix stock. The stock was purchased at an average price of $4.63 per share, with a total value of $189,367.00.
  • On Friday, March 13th, Summer Road Llc acquired 210,800 shares of Ocular Therapeutix stock. The shares were bought at an average price of $4.63 per share, with a total value of $976,004.00.
  • On Tuesday, March 17th, Summer Road Llc acquired 955,062 shares of Ocular Therapeutix stock. The shares were bought at an average price of $5.00 per share, with a total value of $4,775,310.00.

Shares of OCUL opened at $7.22 on Friday. The company has a market capitalization of $329.23 million, a price-to-earnings ratio of -3.68 and a beta of 1.60. Ocular Therapeutix Inc has a fifty-two week low of $2.38 and a fifty-two week high of $8.12. The firm has a 50-day simple moving average of $5.67 and a 200-day simple moving average of $4.73. The company has a debt-to-equity ratio of 5.07, a quick ratio of 4.86 and a current ratio of 4.96.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.01). Ocular Therapeutix had a negative net margin of 1,430.64% and a negative return on equity of 6,659.51%. The company had revenue of $2.61 million during the quarter, compared to analysts’ expectations of $2.66 million. Equities research analysts forecast that Ocular Therapeutix Inc will post -1.13 EPS for the current year.

Several brokerages recently weighed in on OCUL. Zacks Investment Research upgraded Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research note on Friday. HC Wainwright restated a “buy” rating and set a $10.00 target price (up from $8.00) on shares of Ocular Therapeutix in a report on Wednesday, April 29th. Jefferies Financial Group initiated coverage on Ocular Therapeutix in a report on Tuesday, March 17th. They set a “buy” rating and a $8.00 target price on the stock. ValuEngine raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $11.00 price target (up previously from $7.00) on shares of Ocular Therapeutix in a research report on Thursday, March 5th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Ocular Therapeutix has a consensus rating of “Buy” and an average price target of $8.38.

Institutional investors have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Ocular Therapeutix in the 1st quarter valued at $77,000. GWM Advisors LLC purchased a new position in shares of Ocular Therapeutix in the 4th quarter valued at $102,000. Charles Schwab Investment Management Inc. raised its stake in shares of Ocular Therapeutix by 5.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,755 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 5,720 shares during the period. Ieq Capital LLC purchased a new stake in Ocular Therapeutix during the 4th quarter worth $1,011,000. Finally, Citigroup Inc. increased its stake in Ocular Therapeutix by 62.5% during the 4th quarter. Citigroup Inc. now owns 11,376 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 4,375 shares during the period. 47.56% of the stock is owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Featured Story: Bollinger Bands

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.